

Approved



Democratic Republic of the Congo
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		553,941		553,941	100,000	653,941
USAID		24,085,759	9,200,000	33,285,759	4,996,549	38,282,308
DOD		2,905,347		2,905,347	143,437	3,048,784
HHS/CDC	825,000	20,254,646		21,079,646	2,267,694	23,347,340
State/AF		665,627		665,627	0	665,627
Total	825,000	48,465,320	9,200,000	58,490,320	7,507,680	65,998,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency					On Hold Amount	Total
	State	DOD	HHS/CDC	State/AF	USAID		
CIRC	0		0			0	0
HBHC	36,929	50,266	1,949,369	400,000	3,362,361	0	5,798,925
HKID	0	338,695	526,650		175,292	0	1,040,637
HLAB	0	73,339	667,291		282,623	0	1,023,253
HMBL	0		65,825			0	65,825
HMIN	0	102,783	227,801		305,623	0	636,207
HTXD	0	3,339	29,185		10,712,831	0	10,745,355
HTXS	36,929	767,081	6,324,740		6,722,163	0	13,850,913
HVAB	0	0		0	195,000	0	195,000
HVCT	0	311,679	397,246		2,907,728	0	3,616,653
HVMS	258,507	69,005	3,314,576		1,162,821	0	4,804,909
HVOP	46,162	369,307	739,492	165,627	1,098,485	0	2,419,073
HVSI	46,162	102,783	1,497,963		387,353	0	2,034,261

Approved



HVTB	0	152,226	1,652,359		1,441,105	0	3,245,690
IDUP	0	0				0	0
MTCT	92,323	252,684	1,267,434	100,000	840,495	0	2,552,936
OHSS	36,929	152,226	556,166		1,900,674	0	2,645,995
PDCS	0	10,839	820,298		1,051,091	0	1,882,228
PDTX	0	149,095	1,043,251		740,114	0	1,932,460
	553,941	2,905,347	21,079,646	665,627	33,285,759	0	58,490,320



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	5,488,852	0
HKID	836,956	0
HVTB	2,936,809	0
PDCS	1,707,924	0
Total Technical Area Planned Funding:	10,970,541	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	705,000	0
HVSI	1,516,244	0
OHSS	2,238,711	0
Total Technical Area Planned Funding:	4,459,955	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMIN	572,462	0
HVAB	195,000	0
HVCT	3,433,885	0
HVOP	2,248,520	0
MTCT	2,252,691	0
Total Technical Area Planned Funding:	8,702,558	0

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	10,635,809	0
HTXS	13,540,938	0
PDTX	1,755,312	0
Total Technical Area Planned Funding:	25,932,059	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	245,841
	Number of new ANC and L&D clients	253,328
	By: Known positives at entry	1,135
	By: Number of new positives identified	3,115
	Sum of Positives Status disaggregates	4,250
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	0
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNUs ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	245,841
	New on ART	3,364
	Already on ART at beginning of current pregnancy	796
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	60,957
	Total number of people in the target population	370,845
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	



	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	426
	Aggregated Age/sex: 15+ Male	49,162
	Aggregated Age/sex: <15 Female	402
	Aggregated Age/sex: 15+ Female	11,408
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	n/a



	minimum standards required (DSD)	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	25,000
	Total estimated number of key population in the catchment area	30,961
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,500
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,500
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are NOT sex workers (Numerator: Number of	0



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	20,000
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	0



	minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	1,876
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	4,962
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	24,123
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0



	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	884,011
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	5
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex:		



	Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex:	



	Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	31,198
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	221,961
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	45,802
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	585,047
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	1,015
	Test Result by Aggregated Age and Sex: Positive 15+ Male	8,456
	Test Result by Aggregated Age and Sex: Positive <15 Female	1,488
	Test Result by Aggregated Age and Sex: Positive 15+ Female	15,137
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	96
	Age/sex: 1-9	121
	Service Delivery Point	0



	(Community): Index testing	
	Service Delivery Point	0
	(Community): Homebased testing	
	Service Delivery Point	34,153
	(Community): Mobile testing	
	Service Delivery Point	0
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility):	
	Inpatient	123,474
	Service Delivery Point (Facility):	
	Outpatient	287,441
	Service Delivery Point (Facility):	
	Pediatric	67,463
	Service Delivery Point (Facility):	
	Malnutrition facilities	46,538
	Service Delivery Point (Facility):	
	Other PITC	46,533
	Service Delivery Point (Facility):	
		11,461



VCT	
Service Delivery Point (Facility): VMMC	0
Service Delivery Point (Facility): PMTCT	243,940
Service Delivery Point (Facility): TB Clinics	17,824
Service Delivery Point (Facility): Index testing	5,264
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	16,990
	Total number of registered new and relapsed TB cases, during the reporting period.	17,746
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24	



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	887
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,999
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	698
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,444
	Result: Known HIV positive at service entry	



	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	37,549



	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	2,483
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	3,722
	Sum of Age/Sex disaggregates	6,205
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS	



	countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS	



	countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS	



	countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS	



	countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	



	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	14,668
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	16,676
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on	2,488



	ART during TB treatment during the reporting period	
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,737
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of	



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,318
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	86
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented	980



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Female 15+</p>	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	58,001
	Screened for TB by Age/Sex:<15 Male	2,879
	Screened for TB by Age/Sex: 15+ Male	29,610
	Screened for TB by Age/Sex:<15 Female	2,388
	Screened for TB by Age/Sex: 15+ Female	23,173
	Screen Result: Screened Positive for TB	11,565
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	10,633
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	8,878
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,288



	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	603
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	1,970
	By infants who received their first virologic HIV test between 2 and 12 months of age	2,069
	Sum of Infant Age disaggregates	4,039
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	38
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive	44



	virological test result within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	71,850
	Age/Sex: 15-19 Male	0
	Age/Sex: 15-19 Female	6
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	3,458
	Aggregated Age/Sex: 15+ Male	17,375
	Aggregated Age/Sex: <15 Female	5,143
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	46,006
	Sum of Aggregated Age/Sex <15	8,601
	Sum of Aggregated Age/Sex 15+	63,381
	Sum of Aggregated Age/Sex disaggregates	71,982
	Age/Sex: <1	5
	Age/Sex: <1-9	27
	Age/Sex: 10-14 Male	0
	Age/Sex: 10-14 Female	4
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	0
	Age/Sex: 25-49 Male	0
	Age/Sex: 50+ Male	0
	Age/Sex: 20-24 Female	0
Age/Sex: 25-49 Female	0	
Age/Sex: 50+ Female	0	



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	23,616
	By Age/Sex: <1	14
	By Age/Sex: 1-9	4
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	0
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	0
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	0
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	874
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	6,376
	Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	1,309	
Aggregated Grouping by Age/Sex: 15+ Female	15,079	
Sum of Aggregated Age/Sex disaggregates	23,638	



	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	30,892
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	44,072
	Numerator: Indication: Routine	30,271
	Numerator: Indication: Targeted	622
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication:	



	1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication:	



	50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	43,078
	Denominator: Indication: Targeted	893
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by	



	Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex:	1,206



	<15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	7,869
	Numerator Aggregated Age/Sex: <15 Female	1,826
	Numerator Aggregated Age/Sex: 15+ Female	19,994
	Denominator Aggregated Age/Sex: <15 Male	1,732
	Denominator Aggregated Age/Sex: 15+ Male	11,195
	Denominator Aggregated Age/Sex: <15 Female	2,590
	Denominator Aggregated Age/Sex: 15+ Female	28,455
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,238
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,017
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still	1



	alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on	



	treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at	



	12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	385
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on	3,109



	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	589
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,185
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	495
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,843
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	744



	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,927
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	501
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	407
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	366
	CD4: Number of laboratories that perform this testing	15
	CD4: Number of laboratories that participate in this PT program	15
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	15
	Early infant diagnostics: Number of laboratories that perform this testing	44
	Early infant diagnostics: Number of	20



	laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	20
	HIV viral load: Number of laboratories that perform this testing	0
	HIV viral load: Number of laboratories that participate in this PT program	0
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	15
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	15
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	15
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful	1



	passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	
	Number of HIV Test Kits purchased	1
	Number of HIV CD4 Reagents purchased	1
	Number of Condoms purchased	0
	Number of HIV Viral Load Reagents purchased	1
	Number of HIV ARVs purchased	1
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	899,197
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	133,534
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	703,683
	Condoms: Dollars planned (COP)/ spent (Actual)	0
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	7,694,547



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
11054	Population Services International	NGO	U.S. Department of Defense	GHP-State	2,794,046
13017	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	165,368
13094	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	268,034
13623	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13730	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease Control and Prevention		
14831	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	371,627
16934	VOICE OF AMERICA	NGO	U.S. Department of State/Bureau of African Affairs	GHP-State	294,000
16963	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,168,904
17177	SANRU	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
17628	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	0
17630	Education Development Center	NGO	U.S. Agency for International Development	GHP-State	0
17633	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	0
17636	Population Services International	NGO	U.S. Agency for International Development	GHP-USAID	600,000



18090	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	1,300,000
18091	Pathfinder International	NGO	U.S. Agency for International Development	GHP-State	600,000
18092	TBD	TBD	Redacted	Redacted	Redacted
18093	TBD	TBD	Redacted	Redacted	Redacted
18094	Pathfinder International	NGO	U.S. Agency for International Development	GHP-USAID	2,700,000
18096	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	8,793,191
18097	TBD	TBD	Redacted	Redacted	Redacted
18316	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	723,244
18370	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	15,562,193



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 11054	Mechanism Name: HIV/AIDS activities in the DRC Armed Forces
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,794,046	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,794,046	
Funding Source	Funding Amount
GHP-State	2,794,046

Cross-Cutting Budget Attribution(s)

Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	11054
----------------------	--------------



Mechanism Name: HIV/AIDS activities in the DRC Armed Forces			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	46,927	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	335,356	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	7,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	308,340	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	365,968	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	249,901	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	763,742	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	146,312	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,740
PMTCT_ART_DSD	New on ART	268
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,740
PMTCT_STAT_DSD	Number of new ANC and L&D clients	11,754
PMTCT_STAT_DSD	By: Known positives at entry	0
PMTCT_STAT_DSD	By: Number of new positives identified	282
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	282
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	46,325
PP_PREV_DSD	Total number of people in the target population	352,715
PP_PREV_DSD	Aggregated Age/sex: <15 Male	93



PP_PREV_DSD	Aggregated Age/sex: 15+ Male	38,357
PP_PREV_DSD	Aggregated Age/sex: <15 Female	139
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	7,736
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,053
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,160
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	22,035
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	806
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	27,052
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,966
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	49,087
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	51,053
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	51
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	970
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	35
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	956
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	11,153
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	20,124
HTC_TST_DSD	Service Delivery Point (Facility): VCT	6,191
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	11,740
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,845
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,845
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	1,845



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	90
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,201
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	39
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	515
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,891
OVC_SERV_DSD	Age/Sex: 18+ Male	601
OVC_SERV_DSD	Age/Sex: 18+ Female	902
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,503
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	555
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	833
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	184
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	184
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	120



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	51
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,598
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	117
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,044
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	132
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	2,305
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	920
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	920
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	782
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	92
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	46
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	268
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	268
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,840
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	123
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,152
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	139
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,426
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	262
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,578
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,840
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,428
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	7
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	664
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	8
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	749
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,428
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	662
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	883
TX_PVLS_DSD	Numerator: Indication: Routine	629
TX_PVLS_DSD	Numerator: Indication: Targeted	33
TX_PVLS_DSD	Denominator: Indication: Routine	836
TX_PVLS_DSD	Denominator: Indication: Targeted	47
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	304
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	351
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	4
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	406



TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	5
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	468
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,177
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,453
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	541
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	624
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	668
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	770
------------	---	-----

Implementing Mechanism Details

Mechanism ID: 13017	Mechanism Name: Global Laboratory Capacity Strengthening Program
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 165,368	
Applied Pipeline Amount: 404,632	
Total All Funding Sources and Applied Pipeline Amount: 570,000	
Funding Source	Funding Amount
GHP-State	165,368

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13017		
Mechanism Name:	Global Laboratory Capacity Strengthening Program		
Prime Partner Name:	American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	70,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	25,368	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13094	Mechanism Name: Association of Public Health Laboratories Centrally funded CoAG
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 268,034	
Applied Pipeline Amount: 31,966	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	268,034

Cross-Cutting Budget Attribution(s)

Human Resources for Health	20,000
----------------------------	--------



Budget Code Information

Mechanism ID: 13094			
Mechanism Name: Association of Public Health Laboratories Centrally funded CoAG			
Prime Partner Name: Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	68,034	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13623	Mechanism Name: Providing Capacity-Building Assistance to Government and Indigenous Congolese Organizations to Improve HIV/AIDS Service Delivery in the Democratic Republic of Congo under PEPFAR		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: FHI 360			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13623		
Mechanism Name:	Providing Capacity-Building Assistance to Government and Indigenous Congolese Organizations to Improve HIV/AIDS Service Delivery in the		
Prime Partner Name:	Democratic Republic of Congo under PEPFAR		
	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13730	Mechanism Name: Malamu
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13730			
Mechanism Name: Malamu			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14831	Mechanism Name: Small Grant Programs
Funding Agency: State/AF	Procurement Type: Inter-Agency Agreement
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 371,627	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 371,627	
Funding Source	Funding Amount
GHP-State	371,627

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	20,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Gender: GBV	120,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	20,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients

Budget Code Information

Mechanism ID: 14831			
Mechanism Name: Small Grant Programs			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	71,627	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	100,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16934	Mechanism Name: Voice of America: Votre Sante, Votre Avenir
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: VOICE OF AMERICA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 294,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 294,000	
Funding Source	Funding Amount
GHP-State	294,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	15,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 16934			
Mechanism Name: Voice of America: Votre Sante, Votre Avenir			
Prime Partner Name: VOICE OF AMERICA			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	94,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16963	Mechanism Name: Increase Access to Comprehensive HIV/AIDS Prevention Care and Treatment Services in the Democratic Republic of Congo under (PEPFAR) (KIMIA)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,168,904	
Applied Pipeline Amount: 331,096	
Total All Funding Sources and Applied Pipeline Amount: 4,500,000	
Funding Source	Funding Amount
GHP-State	4,168,904

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 16963			
Mechanism Name: Increase Access to Comprehensive HIV/AIDS Prevention Care and Treatment Services in the Democratic Republic of Congo under			
Prime Partner Name: (PEPFAR) (KIMIA)			
Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	720,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	220,165	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	201,739	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	440,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,707,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,848
PMTCT_ART_DSD	New on ART	364
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	164
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,848
PMTCT_STAT_DSD	Number of new ANC and L&D clients	41,078
PMTCT_STAT_DSD	By: Known positives at entry	188
PMTCT_STAT_DSD	By: Number of new positives identified	350
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	538
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	500



KP_PREV_DSD	Total estimated number of key population in the catchment area	625
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	50
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	450
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	62
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	563
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	131,669
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,537
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,108
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,806
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	88,218
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	11,343
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	120,326
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	131,669
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	140



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,127
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	213
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,123
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	19,098
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	44,561
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	10,209
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	7,162
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	7,162
HTC_TST_DSD	Service Delivery Point (Facility): VCT	796
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	39,658
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,227
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	796
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,122
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,227
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	107
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,104
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	826
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	1,449



	HIV/AIDS	
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	580
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	869
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	232
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	256
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	90
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	8,277
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	414
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	4,301
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	331
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,231
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,650
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent:	1,485



	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,238
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	162
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	84
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	229
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	282
PMTCT_EID_DSD	Sum of Infant Age disaggregates	511
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	2
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,346
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	507
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,353
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	760
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	6,726
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,267
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,079
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,346
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,294
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	130
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	831
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	190
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,143
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,294
TX_PVLS_DSD	Number of adults and pediatric patients on ART with	5,070



	suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,243
TX_PVLS_DSD	Numerator: Indication: Routine	5,020
TX_PVLS_DSD	Numerator: Indication: Targeted	50
TX_PVLS_DSD	Denominator: Indication: Routine	7,170
TX_PVLS_DSD	Denominator: Indication: Targeted	73
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	203
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,266
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	308
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	3,293
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	290
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,812
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	435
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	4,706
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,303
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,630
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	330
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	847



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	409
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,060
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	65
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	54
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	46

Implementing Mechanism Details

Mechanism ID: 17177	Mechanism Name: SANRU Clinical and PMTCT Scale-up
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: SANRU	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	1,000,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	20,000
----------------------------	--------

Budget Code Information

Mechanism ID: 17177			
Mechanism Name: SANRU Clinical and PMTCT Scale-up			
Prime Partner Name: SANRU			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,508	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	30,500	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	69,942	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	3,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	251,050	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	75,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,154
PMTCT_ART_DSD	New on ART	196
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	25
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	13,154



	their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	13,592
PMTCT_STAT_DSD	By: Known positives at entry	27
PMTCT_STAT_DSD	By: Number of new positives identified	192
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	219
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,059
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,503
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,508
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,253
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,795
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,756
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	21,303
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	25,059
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	51
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	161
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	76
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	325
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,827
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	4,265
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	3,372
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	688
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	688
HTC_TST_DSD	Service Delivery Point (Facility): VCT	78



HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	13,154
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	908
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	79
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	863
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	908
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	42
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	453
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	342
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	165
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	182
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	96

TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	66
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,813
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	89
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	937
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	75
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	709
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	362
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	326
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	273
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	41
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	14
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	96
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	117
PMTCT_EID_DSD	Sum of Infant Age disaggregates	213
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral	2,269



	therapy (ART)	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	131
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	467
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	195
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,475
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	326
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,942
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,268
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	572
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	41
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	99
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	68
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	372
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	580
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,110
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,589
TX_PVLS_DSD	Numerator: Indication: Routine	1,055
TX_PVLS_DSD	Numerator: Indication: Targeted	55
TX_PVLS_DSD	Denominator: Indication: Routine	1,509
TX_PVLS_DSD	Denominator: Indication: Targeted	80
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	42
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	277
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	69
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	723
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	68
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	391
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	95



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,034
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	421
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	524
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	115
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	273
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	138
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	343



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	30
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	24
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	18

Implementing Mechanism Details

Mechanism ID: 17628	Mechanism Name: Coordinating Comprehensive Care for Children (4Children)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 1,067,349	
Total All Funding Sources and Applied Pipeline Amount: 1,067,349	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 17628			
Mechanism Name: Coordinating Comprehensive Care for Children (4Children)			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,234
OVC_SERV_DSD	Age/Sex: 18+ Male	1,094
OVC_SERV_DSD	Age/Sex: 18+ Female	1,640
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,734
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	7,438
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	8,062

Implementing Mechanism Details

Mechanism ID: 17630	Mechanism Name: Enhancing Services and Linkages for Children affected by HIV and AIDS (ELIKIA)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Education Development Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 3,429,200	
Total All Funding Sources and Applied Pipeline Amount: 3,429,200	
Funding Source	Funding Amount



GHP-State	0
-----------	---

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17630		
Mechanism Name:	Enhancing Services and Linkages for Children affected by HIV and AIDS		
Prime Partner Name:	(ELIKIA)		
Prime Partner Name:	Education Development Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,123
OVC_SERV_DSD	Age/Sex: 18+ Male	788
OVC_SERV_DSD	Age/Sex: 18+ Female	1,180
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,968
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	5,354
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,801

Implementing Mechanism Details

Mechanism ID: 17633	Mechanism Name: Livelihoods and Food Security Technical Assistance (LIFT) II
----------------------------	---

Approved



Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17633			
Mechanism Name: Livelihoods and Food Security Technical Assistance (LIFT) II			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17636	Mechanism Name: SIFPO
Funding Agency: USAID	Procurement Type: Contract



Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 600,000	
Funding Source	Funding Amount
GHP-USAID	600,000

Cross-Cutting Budget Attribution(s)

Condom programming	300,000
--------------------	---------

Budget Code Information

Mechanism ID: 17636			
Mechanism Name: SIFPO			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	450,000	0
------------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,345
PP_PREV_DSD	Total number of people in the target population	4,183
PP_PREV_DSD	Aggregated Age/sex: <15 Male	169
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,740
PP_PREV_DSD	Aggregated Age/sex: <15 Female	133
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,306
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0
KP_PREV_DSD	Total estimated number of key population in the catchment area	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	0

Implementing Mechanism Details

Mechanism ID: 18090	Mechanism Name: Linkages Across the Continuum of HIV Services for Key Populations Affected by HIV (Linkages)
Funding Agency: USAID	Procurement Type: Grant



Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,300,000	
Applied Pipeline Amount: 500,000	
Total All Funding Sources and Applied Pipeline Amount: 1,800,000	
Funding Source	Funding Amount
GHP-State	500,000
GHP-USAID	800,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
Key Populations: MSM and TG	375,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	375,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs



	and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	18090		
Mechanism Name:	Linkages Across the Continuum of HIV Services for Key Populations		
Prime Partner Name:	Affected by HIV (Linkages)		
	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	390,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	375,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	10,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,050
PP_PREV_DSD	Total number of people in the target population	6,550
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	5,050
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	0



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	15,000
KP_PREV_DSD	Total estimated number of key population in the catchment area	18,460
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,500
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,500
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	4,962
KP_PREV_DSD	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	13,498
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,750
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,250
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	23,000
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	23,000
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	339
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,011
HTC_TST_DSD	Service Delivery Point (Community): Index testing	0
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	23,000
HTC_TST_DSD	Service Delivery Point (Community): Other	0

Implementing Mechanism Details

Mechanism ID: 18091	Mechanism Name: Kipa Ya Mupia/Evidence to Action - PROSANI Plus
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 600,000	
Funding Source	Funding Amount
GHP-State	600,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	30,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 18091			
Mechanism Name: Kipa Ya Mupia/Evidence to Action - PROSANI Plus			
Prime Partner Name: Pathfinder International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	44,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	25,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	12,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	6,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	53,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	94,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	230,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	30,000	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,140
PMTCT_ART_DSD	New on ART	180
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	60
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,140
PMTCT_STAT_DSD	Number of new ANC and L&D clients	14,575
PMTCT_STAT_DSD	By: Known positives at entry	132
PMTCT_STAT_DSD	By: Number of new positives identified	120
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	252
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,132
PP_PREV_DSD	Total number of people in the target population	1,411
PP_PREV_DSD	Aggregated Age/sex: <15 Male	76
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	780
PP_PREV_DSD	Aggregated Age/sex: <15 Female	60
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	584
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,436
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,780
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,137
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,667
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	22,852



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,447
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	29,989
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	34,436
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	62
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	248
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	90
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	416
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	4,099
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	7,505
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	3,988
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	1,539
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,539
HTC_TST_DSD	Service Delivery Point (Facility): VCT	175
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	13,830
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,586
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	175
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,509
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,587
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	770
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	68



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	597
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	292
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	324
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	151
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,052
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	104
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,033
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	89
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	792
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	412

TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	371
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	304
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	44
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	19
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	101
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	123
PMTCT_EID_DSD	Sum of Infant Age disaggregates	224
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	8
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	11
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,102
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	277
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	757
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	412
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,669
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	689
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,426
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,115
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	921
TX_NEW_DSD	By Age/Sex: 20-24 Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	47
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	200
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	81



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	595
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	923
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	44
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	20
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	20
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	15
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	15
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	15
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	44
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	20
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	20
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	15
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	15
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing	15



	criteria in this PT program	
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

Implementing Mechanism Details

Mechanism ID: 18092	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18093	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18094	Mechanism Name: KIPA /EVIDENCE TO ACTION-PROVIC PLUS
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 2,700,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,700,000	
Funding Source	Funding Amount
GHP-USAID	2,700,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	135,000
Gender: GBV	25,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	18094		
Mechanism Name:	KIPA /EVIDENCE TO ACTION-PROVIC PLUS		
Prime Partner Name:	Pathfinder International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	297,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	171,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	55,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	29,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	204,075	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	59,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	69,925	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	168,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	142,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,477
PMTCT_ART_DSD	New on ART	675
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	134
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,477
PMTCT_STAT_DSD	Number of new ANC and L&D clients	44,835
PMTCT_STAT_DSD	By: Known positives at entry	226
PMTCT_STAT_DSD	By: Number of new positives identified	658
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	884
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,775
PP_PREV_DSD	Total number of people in the target population	1,775
PP_PREV_DSD	Aggregated Age/sex: <15 Male	88
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	931
PP_PREV_DSD	Aggregated Age/sex: <15 Female	70
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	686
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	167,741
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	6,104



	ONLY: <15 Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	40,878
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,110
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	111,649
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,214
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	152,527
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	167,741
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	218
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,574
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	321
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,799
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	27,840
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	56,749
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	13,692
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	10,577
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	10,568
HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,219
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	43,084
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,798
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,214
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,688
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,806
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	145



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,365
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	130
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,049
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	376
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	451
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	212
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	140
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during	12,089

	the reporting period.	
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	661
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	6,181
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	543
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	4,705
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,342
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,216
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,838
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	286
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	125
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	529
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	240
PMTCT_EID_DSD	Sum of Infant Age disaggregates	769
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	4
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	25,280
TX_CURR_DSD	Age/Sex: 15-19 Male	0
TX_CURR_DSD	Age/Sex: 15-19 Female	0
TX_CURR_DSD	Sum of age/sex disaggregates	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,455
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,232
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,168
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,420
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,623



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	21,652
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	25,275
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_CURR_DSD	Age/Sex: 10-14 Male	0
TX_CURR_DSD	Age/Sex: 10-14 Female	0
TX_CURR_DSD	Age/Sex: 20-24 Male	0
TX_CURR_DSD	Age/Sex: 25-49 Male	0
TX_CURR_DSD	Age/Sex: 50+ Male	0
TX_CURR_DSD	Age/Sex: 20-24 Female	0
TX_CURR_DSD	Age/Sex: 25-49 Female	0
TX_CURR_DSD	Age/Sex: 50+ Female	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,899
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	189
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,311
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	276
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,121
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,897
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	165
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	165
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	165

Implementing Mechanism Details

Mechanism ID: 18096	Mechanism Name: Increase Access to Comprehensive HIV/AIDS Prevention, Care, and Treatment Services in DRC under PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 8,793,191	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,793,191	
Funding Source	Funding Amount
GHP-State	8,793,191

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
Key Populations: MSM and TG	30,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Gender: Gender Equality	20,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Condom programming	5,000
Motor Vehicles: Purchased	159,000



Budget Code Information

Mechanism ID: 18096			
Mechanism Name: Increase Access to Comprehensive HIV/AIDS Prevention, Care, and Treatment Services in DRC under PEPFAR			
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	981,229	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	281,435	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	366,337	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	102,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	96,826	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	54,462	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	421,756	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,188,646	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	550,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	65,874
PMTCT_ART_DSD	New on ART	872
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	212
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	65,874
PMTCT_STAT_DSD	Number of new ANC and L&D clients	67,909
PMTCT_STAT_DSD	By: Known positives at entry	281
PMTCT_STAT_DSD	By: Number of new positives identified	825
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,106
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	9,500
KP_PREV_DSD	Total estimated number of key population in the catchment area	11,876
KP_PREV_DSD	By key population type: Men who have sex with men	1,450

	who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,050
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	1,814
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	10,062
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	249,290
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,256
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	61,621
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,388
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	167,025
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	20,644
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	228,646
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	249,290
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	270
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,290
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	403



	Female	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,349
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	38,650
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	90,185
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	18,573
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	14,490
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	14,490
HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,614
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	65,582
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	4,090
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,616
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,882
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,074
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	188
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,027
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	153
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,514
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,852
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0

OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	741
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,111
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	568
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	630
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	29
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	292
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	224
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	15,139
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	756
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	7,872
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	607
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	5,904
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,028
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,725



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,271
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	303
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	151
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	479
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	573
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,052
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	7
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	8
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,931
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	933
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,287
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,405
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	12,306
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,338
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,593
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	18,931
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: 10-14 Female	2
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,704
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	242
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,741
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	364
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,357
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,704



TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,279
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	13,254
TX_PVLS_DSD	Numerator: Indication: Routine	9,083
TX_PVLS_DSD	Numerator: Indication: Targeted	196
TX_PVLS_DSD	Denominator: Indication: Routine	12,977
TX_PVLS_DSD	Denominator: Indication: Targeted	277
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	368
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	2,320
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	558
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	6,033
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	531
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	3,312
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	795
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	8,616
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,878
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,596
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	113
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	722



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	170
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,873
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	145
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	898
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	213
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,340
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	197
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	144
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	117



Implementing Mechanism Details

Mechanism ID: 18097	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18316	Mechanism Name: Strengthening Public Health Capacity and Strategic Information Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 723,244	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 723,244	
Funding Source	Funding Amount
GHP-State	723,244

Cross-Cutting Budget Attribution(s)

Human Resources for Health	20,000
----------------------------	--------

Budget Code Information

Mechanism ID:	18316		
Mechanism Name:	Strengthening Public Health Capacity and Strategic Information Systems		
Prime Partner Name:	UNAIDS - Joint United Nations Programme on HIV/AIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	723,244	0
------------------------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18370	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 15,562,193	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 15,562,193	
Funding Source	Funding Amount
GHP-State	15,562,193

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	90,000
Human Resources for Health	250,000

Budget Code Information

Mechanism ID:	18370
----------------------	--------------



Mechanism Name:	Global Health Supply Chain Program		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,218,682	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	324,809	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	541,348	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	675,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	677,045	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	10,635,809	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,489,500	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	Number of HIV Test Kits purchased	1
INVS_COMD	Number of HIV CD4 Reagents purchased	1
INVS_COMD	Number of Condoms purchased	0
INVS_COMD	Number of HIV Viral Load Reagents purchased	1
INVS_COMD	Number of HIV ARVs purchased	1



INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	899,197
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	133,534
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	703,683
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	7,694,547

Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		20,000		0	20,000	20,000
ICASS		310,000		0	310,000	310,000
Institutional Contractors				0	0	0
Management Meetings/Professional Development		48,672		0	48,672	48,672
Non-ICASS Administrative Costs			200,000	0	200,000	200,000
Staff Program Travel		351,819		0	351,819	351,819
USG Staff Salaries and Benefits - Internationally Recruited			723,720	0	723,720	723,720



USG Staff Salaries and Benefits - Locally Recruited		818,569	76,280	0	894,849	894,849
Total	0	1,549,060	1,000,000	0	2,549,060	2,549,060

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
USG Staff Salaries and Benefits - Locally Recruited		111,301		143,437	111,301	254,738
Total	0	111,301	0	143,437	111,301	254,738

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied



						Pipeline Amount
Capital Security Cost Sharing		506,743		0	506,743	506,743
Computers/IT Services		119,707		0	119,707	119,707
ICASS		730,000		0	730,000	730,000
Management Meetings/Professional Development		122,000		0	122,000	122,000
Non-ICASS Administrative Costs		204,220		0	204,220	204,220
Non-ICASS Motor Vehicles		65,000		0	65,000	65,000
Staff Program Travel		265,000		0	265,000	265,000
USG Renovation		200,000		0	200,000	200,000
USG Staff Salaries and Benefits - Internationally Recruited	825,000	670,941		0	1,495,941	1,495,941
USG Staff Salaries and Benefits - Locally Recruited		1,502,294		0	1,502,294	1,502,294
Total	825,000	4,385,905	0	0	5,210,905	5,210,905

U.S. Department of State

Approved



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
USG Staff Salaries and Benefits - Locally Recruited		553,941		100,000	553,941	653,941
Total	0	553,941	0	100,000	553,941	653,941